This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Participants taking 9 mg of mazdutide lost an average of 11.7% of their body weight, compared to 1.8% in the placebo group.
Why it matters
The results indicate that mazdutide could be an effective treatment for obesity, addressing a significant health issue. Its favorable safety profile is also encouraging for future use.
How the study worked
The study was a randomized, placebo-controlled trial involving multiple ascending doses of mazdutide over 12 to 16 weeks.
What this study cannot tell us
The small sample size and short duration limit the generalizability of the findings.
Read the original research
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
EClinicalMedicine, 54, 101691
Citation
Ji, Linong; Gao, Leili; Jiang, Hongwei; Yang, Jing; Yu, Lei; Wen, Jie; Cai, Chenghang; Deng, Huan; Feng, Liqi; Song, Baili; Ma, Qingyang; Qian, Lei. (2022). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.. EClinicalMedicine, 54, 101691. https://doi.org/10.1016/j.eclinm.2022.101691